Please ensure Javascript is enabled for purposes of website accessibility

Roche's Tecentriq Fails to Help Patients in Muscle-Invasive Bladder Cancer Trial

By Mark Prvulovic - Jan 24, 2020 at 3:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's not the first bladder-cancer related setback for the drug, but it surprised industry experts nonetheless.

Swiss pharmaceutical giant Roche (RHHBY 0.53%) announced today that its cancer-immunology drug, Tecentriq, flopped in a late-stage trial evaluating patients with muscle-invasive, bladder (also known as urothelial) cancer.

Tecentriq was being tested as a monotherapy for patients who had just undergone surgery for urothelial cancer and were at risk of having the cancer return. The drug ended up failing to meet its primary endpoint of delaying the cancer's return, which came as a big surprise to industry experts considering that urothelial cancer was one of the first diseases that Tecentriq was approved for.

Abstract image of a bladder with malignant cancers everywhere.

Image source: Getty Images.

Muscle-invasive urothelial cancer is a condition where cancer spreads into the muscle wall of the bladder but hasn't spread to other parts of the body. "Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival," said Roche's Chief Medical Officer, Levi Garraway, in response to the results.

Further details

This isn't the first time that Tecentriq has flopped in a bladder cancer trial. Back in April 2019, Roche announced that it had thrown in the towel on a phase 1 trial testing non-muscle invasive bladder cancer. In September, another trial showed that Tecentriq just barely outperformed regular chemotherapy in treating bladder cancer.

Tecentriq has already received approval from U.S. and EU healthcare regulators in treating lung cancer (both small-cell and non-small-cell types), urothelial cancer, as well as specific types of breast cancer. While seen as a potential competitor to Merck's cancer superdrug Keytruda, Tecentriq has quite a way to go before it generates anywhere near the same revenue figures that Keytruda is bringing in.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
$39.75 (0.53%) $0.21
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$90.41 (-0.46%) $0.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.